![Thomas Reynolds](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Thomas Reynolds
Director/Miembro de la Junta en MEI PHARMA, INC. .
Fortuna: 1 430 $ al 31/05/2024
Cargos activos de Thomas Reynolds
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
MEI PHARMA, INC. | Director/Miembro de la Junta | 11/02/2013 | - |
Independent Dir/Board Member | 11/02/2013 | - | |
Two Paddles Consulting LLC | Presidente | 01/12/2013 | - |
Historial de carrera de Thomas Reynolds
Antiguos cargos conocidos de Thomas Reynolds.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
TRILLIUM THERAPEUTICS | Director/Miembro de la Junta | 10/03/2014 | 28/04/2021 |
Independent Dir/Board Member | 10/03/2014 | 28/04/2021 | |
SEAGEN INC. | Director Técnico/Científico/I+D | 01/03/2007 | 01/02/2013 |
ZymoGenetics, Inc.
![]() ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | Director Técnico/Científico/I+D | 01/06/2002 | 01/03/2007 |
Somatix Therapy Corp.
![]() Somatix Therapy Corp. BiotechnologyHealth Technology Somatix Therapy Corp. researches, develops, and commercialize proprietary processes for the genetic modification of cells and their use in the treatment of human disease. Somatix's assets include its highly efficient gene transfer technology, broad-based intellectual property, and focused product development programs. The company's most advanced clinical development program, the GVAX cancer vaccine, is in Phase I/II clinical trials for the treatment of metastatic renal cell carcinoma, advanced melanoma, and prostate cancer. It is located in Alameda, CA | Director Técnico/Científico/I+D | - | - |
AmpliPhi Biosciences Corp.
![]() AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | Corporate Officer/Principal | - | - |
Oxford BioTherapeutics Ltd.
![]() Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom. | Director/Miembro de la Junta | 15/01/2014 | - |
Formación de Thomas Reynolds.
Stanford University | Doctorate Degree |
Dartmouth College | Undergraduate Degree |
Estadísticas
Internacional
Estados Unidos | 9 |
Reino Unido | 2 |
Canadá | 2 |
Operativa
Chief Tech/Sci/R&D Officer | 3 |
Director/Board Member | 3 |
Independent Dir/Board Member | 2 |
Sectorial
Health Technology | 8 |
Consumer Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
MEI PHARMA, INC. | Health Technology |
Empresas privadas | 7 |
---|---|
Seagen Inc.
![]() Seagen Inc. Pharmaceuticals: MajorHealth Technology Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. | Health Technology |
ZymoGenetics, Inc.
![]() ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | Health Technology |
Oxford BioTherapeutics Ltd.
![]() Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom. | Health Technology |
Trillium Therapeutics ULC
![]() Trillium Therapeutics ULC BiotechnologyHealth Technology Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada. | Health Technology |
Two Paddles Consulting LLC | |
AmpliPhi Biosciences Corp.
![]() AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | Health Technology |
Somatix Therapy Corp.
![]() Somatix Therapy Corp. BiotechnologyHealth Technology Somatix Therapy Corp. researches, develops, and commercialize proprietary processes for the genetic modification of cells and their use in the treatment of human disease. Somatix's assets include its highly efficient gene transfer technology, broad-based intellectual property, and focused product development programs. The company's most advanced clinical development program, the GVAX cancer vaccine, is in Phase I/II clinical trials for the treatment of metastatic renal cell carcinoma, advanced melanoma, and prostate cancer. It is located in Alameda, CA | Health Technology |
- Bolsa de valores
- Insiders
- Thomas Reynolds
- Experiencia